Evidence map›Paper›PMID 35976559›Full record

ArticleInfection2023

Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency.

Huaie Liu, Weilin Zeng, Pallavi Malla, Chengqi Wang, Seetha Lakshmi, Kami Kim, Lynette Menezes, Zhaoqing Yang, Liwang Cui

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Huaie Liu *Department of Pathogen Biology and Immunology, Kunming Medical University, Kunming, 650500, Yunnan Province, China.
Weilin Zeng *Department of Pathogen Biology and Immunology, Kunming Medical University, Kunming, 650500, Yunnan Province, China.
Pallavi MallaDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, 3720 Spectrum Boulevard, Suite 304, Tampa, FL, 33612, USA.
Chengqi WangCenter for Global Health and Infectious Diseases, University of South Florida, 3720 Spectrum Boulevard, Suite 404, Tampa, FL, 33612, USA.
Seetha LakshmiDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, 3720 Spectrum Boulevard, Suite 304, Tampa, FL, 33612, USA.
Kami KimDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, 3720 Spectrum Boulevard, Suite 304, Tampa, FL, 33612, USA.
Lynette MenezesDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, 3720 Spectrum Boulevard, Suite 304, Tampa, FL, 33612, USA.
Zhaoqing YangDepartment of Pathogen Biology and Immunology, Kunming Medical University, Kunming, 650500, Yunnan Province, China. zhaoqingy92@hotmail.com.
Liwang CuiDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, 3720 Spectrum Boulevard, Suite 304, Tampa, FL, 33612, USA. liwangcui@usf.edu.ORCID http://orcid.org/0000-0002-8338-1974
University of South Florida · USKunming Medical University · CN

Funding

Southeast Asia Malaria Research CenterU19AI089672 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CUI, LIWANG · 2010 to 2023
$28.9M
National Institute of Allergy and Infectious Diseases U19AI089672National Natural Science Foundation of China 31860604National Natural Science Foundation of China U1802286NIAID NIH HHS U19 AI089672Science and Technology Planning Project of Shenzhen Municipality 2018ZF0081
6 · The paper itself

Abstract

backgroundPrimaquine is essential for the radical cure of Plasmodium vivax malaria, but it poses a potential danger of severe hemolysis in G6PD-deficient (G6PDd) patients. This study aimed to determine whether primaquine is safe in a population with high G6PD prevalence but lacking G6PD diagnosis capacity.

methodsIn Myanmar, 152 vivax patients were gender- and age-matched at 1:3 for G6PDd versus G6PD-normal (G6PDn). Their risk of acute hemolysis was followed for 28 days after treatment with the standard chloroquine and 14-day primaquine (0.25 mg/kg/day) regimen.

resultsPatients anemic and non-anemic at enrollment showed a rising and declining trend in the mean hemoglobin level, respectively. In males, the G6PDd group showed substantially larger magnitudes of hemoglobin reduction and lower hemoglobin nadir levels than the G6PDn group, but this trend was not evident in females. Almost 1/3 of the patients experienced clinically concerning declines in hemoglobin, with five requiring blood transfusion.

conclusionsThe standard 14-day primaquine regimen carries a significant risk of acute hemolytic anemia (AHA) in vivax patients without G6PD testing in a population with a high prevalence of G6PD deficiency and anemia. G6PD testing would avoid most of the clinically significant Hb reductions and AHA in male patients.

Indexed as

AntimalarialsGlucosephosphate Dehydrogenase DeficiencyMalaria, VivaxFemaleGlucosephosphate DehydrogenaseHemoglobinsHemolysisHumansMalePlasmodium vivaxPrevalencePrimaquineAntimalarialsGlucosephosphate DehydrogenaseHemoglobinsPrimaquineAnemiaGenderGlucose-6-phosphate dehydrogenaseHemolysisParasitemiaPrimaquine

Identifiers

PMID35976559
PMCPMC9892342
OpenAlexW4292092790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.